Impact of Donor Type and Melphalan Dose on Allogeneic Transplantation Outcomes for Patients with Lymphoma-Reference-Cited by-同舟云学术

Impact of Donor Type and Melphalan Dose on Allogeneic Transplantation Outcomes for Patients with Lymphoma

Published:2019-07 Issue:7 Volume:25 Page:1340-1346
ISSN:1083-8791
Container-title:Biology of Blood and Marrow Transplantation
language:en
Short-container-title:Biology of Blood and Marrow Transplantation

Author:

Saini Neeraj Y.,Saliba Rima M.,Rondon Gabriela,Maadani Farzaneh,Popat Uday,Hosing Chitra M.,Oran Betul,Bashir Qaiser,Olson Amanda^ORCID,Nieto Yago^ORCID,Alousi Amin,Kebriaei Partow,Srour Samer,Mehta Rohtesh,Anderlini Paolo,Shpall Elizabeth J.,Qazilbash Muzaffar H.^ORCID,Khouri Issa F.,Fayad Luis,Lee Hun,Fowler Nathan,Parmar Simrit,Westin Jason,Hagemeister Fredrick,Champlin Richard E.^ORCID,Ciurea Stefan O.^ORCID

Publisher

Elsevier BV

Subject

Transplantation,Hematology

Reference25 articles.

1. Chimeric antigen receptor therapy;June;N Engl J Med,2018

2. Brentuximab vedotin with chemotherapy for stage III or IV Hodgkin's lymphoma;Connors;N Engl J Med,2018

3. Evolution of CLL treatment—from chemoimmunotherapy to targeted and individualized therapy;Burger;Nat Rev Clin Oncol,2018

4. An EBMT registry matched study of allogeneic stem cell transplants for lymphoma: allogeneic transplantation is associated with a lower relapse rate but a higher procedure-related mortality rate than autologous transplantation;Peniket;Bone Marrow Transplant,2003

5. Allogeneic hematopoietic stem cell transplantation for relapsed follicular lymphoma: a combined analysis on behalf of the Lymphoma Working Party of the EBMT and the Lymphoma Committee of the CIBMTR;Sureda;Cancer,2018

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Melphalan Dose in Combination With Fludarabine Affects Gastrointestinal Toxicity and Graft-Versus-Host Disease After Allogeneic Transplantation in Acute Myeloid Leukemia and Myelodysplastic Syndromes;Transplantation and Cellular Therapy;2024-08

2. Long-Term Outcomes of Allogeneic Stem Cell Transplantation for Relapsed/Refractory Hodgkin and Non-Hodgkin Lymphoma: Multi-center Experience from Turkey;Indian Journal of Hematology and Blood Transfusion;2024-07-26

3. Haploidentical Hematopoietic Cell Transplantation;Manual of Hematopoietic Cell Transplantation and Cellular Therapies;2024

4. Relapse after allogeneic transplantation with post-transplant cyclophosphamide: Shattering myths and evolving insight;Blood Reviews;2023-11

5. PTCY-Based Haploidentical Donor Transplantation versus HLA-Matched Related and Unrelated Donor Transplantations in Patients with Refractory or Relapsed Lymphoma—A Matched-Pair Analysis;Cancers;2023-10-31